Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synergistic interactions among antifolates.

R L Kisliuk1

  • 1Department of Biochemistry, Tufts University, 136 Harrison Avenue, Boston, MA, USA. rkisliuk@opal.tufts.edu

Pharmacology & Therapeutics
|March 31, 2000
PubMed
Summary

Combining dihydrofolate reductase inhibitors with antifolates targeting thymidylate synthase or glycinamide ribonucleotide formyltransferase enhances cell death. This synergistic cytotoxicity is amplified by higher folic acid levels and requires polyglutamylatable antifolates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2-Amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines as Nonclassical Antifolate Inhibitors of Thymidylate Synthase.

Journal of medicinal chemistry·2016
Same author

Deaza analogs of folic acid as antitumor agents.

Current pharmaceutical design·2003
Same author

Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.

Journal of medicinal chemistry·2001
Same author

Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.

Journal of medicinal chemistry·2000
Same author

Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.

Journal of medicinal chemistry·2000
Same author

Synthesis of classical and a nonclassical 2-amino-4-oxo-6-methyl-5-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of thymidylate synthase.

Journal of medicinal chemistry·1999

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Dihydrofolate reductase (DHFR) is crucial for folate metabolism.
  • Antifolates targeting thymidylate synthase (TS) or glycinamide ribonucleotide formyltransferase (GARFT) are used in cancer therapy.
  • Synergistic drug interactions can improve therapeutic efficacy.

Purpose of the Study:

  • To investigate synergistic cytotoxicity between DHFR inhibitors and antifolates.
  • To explore the influence of folic acid concentration on these synergistic effects.
  • To identify factors influencing the metabolic basis of synergism.

Main Methods:

  • Quantification of synergistic interactions using alpha, a response surface-based parameter.
  • Analysis of drug combinations in cultured human cell lines.

Related Experiment Videos

  • Evaluation of antifolate polyglutamylatability.

    • Main Results:

    • Significant synergistic cytotoxicity observed when DHFR inhibitors are combined with TS or GARFT inhibitors.
    • Synergism is dependent on medium folic acid concentration, increasing with higher levels.
    • Synergism is observed only with polyglutamylatable TS or GARFT inhibitors.

    Conclusions:

    • Combined DHFR and TS/GARFT inhibition induces potent synergistic cytotoxicity.
    • Folic acid levels critically modulate the efficacy of these drug combinations.
    • Antifolate polyglutamylatability is essential for achieving synergistic effects, suggesting intracellular folate metabolism plays a key role.